Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer

Not yet recruiting

• Conditions: Breast Cancer
• Interventions: Genetic: Genotyping

• Registration Number: NCT05876728
• Lead Sponsor: Sohag University

Brief Summary

Breast cancer is the most frequent cancer in women worldwide. Its incidence is increasing but mortality has decreased in a considerable way due to the combined effect of early detection and improvement in treatment .

Irisin is encoded by the FNDC5 gene, whose expression is controlled by the peroxi- some proliferator activated receptor gamma coactivator 1 alpha (PGC-1α). PGC-1α is a transcriptional co-activator which does not bind directly to DNA. Studies indicated that the estrogen-related receptor alpha (ERRα) could be a factor that plays a role in PGC-1α binding to DNA. ERRα is encoded by the ESRRA gene and is an orphan nuclear receptor, which has two domains. One of them allows the interaction with DNA, and the second one with a ligand. The ERRα structure is similar to that of the estrogen receptor alpha (ERα), but this receptor does not bind to natural estrogens. ERRα interacts with a canonical sequence of the estrogen response elements (ERRE). ERRα and ERα could compete with each other to bind to similar DNA elements. Together, ERRα binds to DNA, in complex with PGC-1α, to regulate the activity of genes such as FNDC5 .

CA15-3, a high molecular weight glycoprotein (300-450 kDa), is produced by the epithelial ducts and acinic breast cells and is then secreted in milk normally. It has been widely used for the prediction of bone metastases in patients with breast cancer .

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2023-05
• Study First Submitted: 2023-05-17
• Study First Submitted QC: 2023-05-17
• Last Update Submitted: 2023-05-17
• Study First Posted: 2023-05-25
• Last Update Posted: 2023-05-25
• Study Start: 2023-06-01
• Primary Completion: 2024-06-01
• Study Completion: 2024-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• histologically confirmed breast cancer

Read More

Exclusion Criteria

• • History of other tumors.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
cases group	Genotyping	50 patient of histologically confirmed breast cancer
control group	Genotyping	50 healthy volunteers with no clinical evidence of any neoplastic disorder

Primary Outcome Measures

Name	Time	Method
find a possible association between irisin gene single nucleotide polymorphism with breast cancer	12 months	- find a possible association between irisin gene single nucleotide polymorphism with breast cancer risk and the distribution of its alleles, in relation to many clinical parameters of the cancer group.

Trial Locations

Locations (1)

Sohag university Hospital; 🇪🇬 Sohag, Egypt